

Contents

List of contributors *page viii*

Part I Introduction

- 1 Genes and psychopharmacology: exploring the interface 3
Bernard Lerer

Part II Clinical background and research design

- 2 From pharmacogenetics to pharmacogenomics of psychotropic drug 21
response
Anil K. Malhotra
- 3 Neuropsychopharmacology: the interface between genes and psychiatric 36
nosology
Thomas A. Ban
- 4 Methodological issues in psychopharmacogenetics 57
Sheldon H. Preskorn
- 5 Statistical approaches in psychopharmacogenetics 72
Fabio Macciardi

Part III Molecular background

- 6 The psychopharmacogenetic–neurodevelopmental interface in serotonergic 95
gene pathways
K. Peter Lesch, Jens Benninghoff, and Angelika Schmitt

v

vi **Contents**

- 7 RNA processing regulation and interindividual variation 127
Colleen M. Niswender and Linda K. Hutchinson

Part IV **Pharmacokinetics**

- 8 Pharmacogenetics of psychotropic drug metabolism 157
Vural Ozdemir, Angela D.M. Kashuba, Vincenzo S. Basile, and James L. Kennedy
- 9 Pharmacogenetics of chiral psychotropic drugs 181
Pierre Baumann and Chin B. Eap

Part V **Specific psychotropic drugs and disorders**

- 10 Clozapine response and genetic variation in neurotransmitter receptor targets 217
David A. Collier, Maria J. Arranz, Sarah Osborne, Katherine J. Aitchison, Janet Munro, Dalu Mancama, and Robert W. Kerwin
- 11 Genetic factors underlying drug-induced tardive dyskinesia 245
Ronnen H. Segman and Bernard Lerer
- 12 Functional gene-linked polymorphic regions in pharmacogenetics 267
Marco Catalano
- 13 Alternative phenotypes and the pharmacogenetics of mood and anxiety disorders 283
Emanuela Mundo and James L. Kennedy
- 14 Pharmacogenetics of anxiolytic drugs and the GABA-benzodiazepine receptor complex 300
Smita A. Pandit, Spilios V. Argyropoulos, Patrick G. Kehoe, and David J. Nutt
- 15 Genetic factors and long-term prophylaxis in bipolar disorder 320
Martin Alda
- 16 Genetic influences on responsiveness to anticonvulsant drugs 333
Thomas N. Ferraro
- 17 Apolipoprotein E as a marker in the treatment of Alzheimer's disease 360
Keith Schappert, Pierre Sevigny, and Judes Poirier

vii **Contents**

- 18 Genetic variation and drug dependence risk factors 372
Joel Gelernter and Henry Kranzler

Part VI **Pharmacogenetics and brain imaging**

- 19 Brain imaging and pharmacogenetics in Alzheimer's disease and
schizophrenia 391
Steven G. Potkin, James L. Kennedy, and Vincenzo S. Basile

Part VII **Industry perspectives**

- 20 Pharmacogenetics in psychotropic drug discovery and development 401
William Z. Potter, AnnCatherine Van Lone, and Larry Altstiel
- 21 High-throughput single nucleotide polymorphism genotyping 420
Anne Shalom and Ariel Darvasi
- Index* 439